In-Silico Screening of Phytochemicals for Identification of Alternative Therapy for Thyroid Cancer

Year : 2025 | Volume : 02 | Issue : 02 | Page :
    By

    Swapnesh Bhaduri,

  1. Student, Department of Pharmacy, National Institute of Pharmaceutical Education and Research, Kolkata, West Bengal, India

Abstract

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_200790’);});Edit Abstract & Keyword

Thyroid cancer remains a significant health concern globally, necessitating the exploration of novel therapeutic alternatives to improve treatment outcomes. This study targets COT kinase (Cancer Osaka Thyroid Kinase), a protein implicated in the progression of thyroid cancer, using molecular docking methods with various phytochemicals to identify potential therapeutic compounds. PyRx and Discovery Studio were employed to evaluate the interactions and binding affinities of a diverse set of natural compounds with the target protein. A comprehensive selection of 150 alkaloids, 150 terpenoids, and 149 flavonoids were screened to assess their potential efficacy in modulating COT kinase activity. Through silico analysis, the study aims to identify phytochemicals that exhibit strong binding affinities with COT kinase and could potentially serve as lead compounds for the development of new therapeutic agents. By exploring a wide variety of natural compounds, the research seeks to broaden the scope of potential treatment options for thyroid cancer, particularly for cases where existing therapies may be less effective or associated with significant side effects. The findings from this study will contribute valuable insights into the molecular interactions between phytochemicals and COT kinase, offering a foundation for future research and development in the field of thyroid cancer treatment. By identifying compounds with promising therapeutic potential, this research may pave the way for the development of more targeted and effective treatments for thyroid cancer, ultimately improving patient outcomes and quality of life.

Keywords: In-silico, docking, phytochemicals, thyroid cancer, COT kinase

[This article belongs to International Journal of Toxins and Toxics ]

How to cite this article:
Swapnesh Bhaduri. In-Silico Screening of Phytochemicals for Identification of Alternative Therapy for Thyroid Cancer. International Journal of Toxins and Toxics. 2025; 02(02):-.
How to cite this URL:
Swapnesh Bhaduri. In-Silico Screening of Phytochemicals for Identification of Alternative Therapy for Thyroid Cancer. International Journal of Toxins and Toxics. 2025; 02(02):-. Available from: https://journals.stmjournals.com/ijtt/article=2025/view=0


document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_200790’);});Edit

References

  1. Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol). 2010;22(6):395–404.
  2. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013; 2013:965212.
  3. Kitahara CM, Schneider AB. Epidemiology of thyroid cancer. Cancer Epidemiol Biomarkers Prev. 2022;31(7):1284–97.
  4. Lubitz CC, Sosa JA. The changing landscape of papillary thyroid cancer: epidemiology, management, and the implications for patients. Cancer. 2016;122(24):3754–9.
  5. Seib CD, Sosa JA. Evolving understanding of the epidemiology of thyroid cancer. Endocrinol Metab Clin North Am. 2019;48(1):23–35.
  6. Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. Nat Rev Endocrinol. 2016;12(11):646–53.
  7. Figge JJ. Epidemiology of thyroid cancer. In: Thyroid cancer: a comprehensive guide to clinical management. 2016. p. 9–15.
  8. Mamashov NM. New thyroid cancer treatment strategies. Nauchnoye obozreniye. Med nauki. 2023.
  9. Brito JP, Moon JH, Zeuren R, Kong SH, Kim YG, Iñiguez-Ariza NM, et al. Thyroid cancer treatment choice: a pilot study of a tool to facilitate conversations with patients with papillary microcarcinomas considering treatment options. Thyroid. 2018;28(10):1325–31.
  10. Yoo Y, Yoon SJ, Kim SY, Lee DW, Um S, Hyun H, et al. A local drug delivery system based on visible light-cured glycol chitosan and doxorubicin⋅hydrochloride for thyroid cancer treatment in vitro and in vivo. Drug Deliv. 2018;25(1):1664–71.
  11. Marano F, Frairia R, Rinella L, Argenziano M, Bussolati B, Grange C, et al. Combining doxorubicin-nanobubbles and shockwaves for anaplastic thyroid cancer treatment: preclinical study in a xenograft mouse model. Endocr Relat Cancer. 2017;24(6):275–86.
  12. Yang L, Ma J, Lei P, Yi J, Ma Y, Huang Z, et al. Advances in antioxidant applications for combating 131I side effects in thyroid cancer treatment. Toxics. 2023;11(6):529.
  13. Greco A, Coperchini F, Croce L, Magri F, Teliti M, Rotondi M. Drug repositioning in thyroid cancer treatment: the intriguing case of anti-diabetic drugs. Front Pharmacol. 2023; 14:1303844.
  14. Ghosh C, Gunda V, Hu J, Zhang L, Zhang YQ, Shen M, et al. Abstract 5505: Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer and act by enhanced activation of multiple cell death pathways. Cancer Res. 2023.
  15. Colombo C, Giancola N, Fugazzola L. Personalized treatment for differentiated thyroid cancer: current data and new perspectives. Minerva Endocrinol (Torino). 2021;46(1):62–89.
  16. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73:17–48.
  17. American Thyroid Association. Thyroid cancer (Papillary and Follicular) [Brochure]. 2022. Available from:https://www.thyroid.org/wp-content/uploads/patients/brochures/ThyroidCancer_brochure.pdf
  1. Carling T, Udelsman R. Thyroid cancer. Annu Rev Med. 2014; 65:125–37.
  2. Costa RV, Pakenham KI. Associations between benefit finding and adjustment outcomes in thyroid cancer. Psychooncology. 2012;21(7):737–44.
  3. Bonnefond S, Davies TF. Thyroid cancer—risks and causes. Oncol Hematol Rev. 2014;10(2):144–51.
  4. Kusić Z, Prgomet D. Karcinom štitne i doštitne žljezde. In: Prgomet D, editor. Tumori glave i vrata. Zagreb: Medicinska naklada; 2019. p. 262–73.
  5. Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. Cancer. 2000;89(1):202–17.
  6. Aschebrook-Kilfoy B, Kaplan EL, Chiu BC, Angelos P, Grogan RH. The acceleration in papillary thyroid cancer incidence rates is similar among racial and ethnic groups in the United States. Ann Surg Oncol. 2013.
  7. Mulita F, Anjum F. Thyroid adenoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
  8. Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, Sponziello M. Update on fundamental mechanisms of thyroid cancer. Front Endocrinol (Lausanne). 2020; 11:102.
  9. Iqbal A, Azhar S, Ibrahim NA, et al. Thyroid cancer risk factors and Pakistani university students’ awareness towards its preventive practice. J Oncol Pharm Pract. 2021; 27:570–8.
  10. Li Y. Pyrvinium pamoate can overcome artemisinin’s resistance in anaplastic thyroid cancer. BMC Complement Med Ther. 2021; 21:156.
  11. Li T, Zhao N, Lu J, Zhu Q, Liu X, Hao F, et al. Epigallocatechin gallate (EGCG) suppresses epithelial-mesenchymal transition (EMT) and invasion in anaplastic thyroid carcinoma cells through blocking of TGF-β1/smad signaling pathways. Bioengineered. 2019;10:282–91.
  12. Nguyen QT, Lee EJ, Huang MG, Park YI, Khullar A, Plodkowski RA. Diagnosis and treatment of patients with thyroid cancer. Am Health Drug Benefits. 2015;8(1):30–40.
  13. Duan L, Yang Z, Jiang X, Zhang J, Guo X. Oleanolic acid inhibits cell proliferation, migration and invasion and induces SW579 thyroid cancer cell line apoptosis by targeting forkhead transcription factor A. Anticancer Drugs. 2019;30(8):812–20.
  14. Sharma N, Sharma VK, Manikyam HK, Krishna AB. Ergot alkaloids: a review on therapeutic applications. Eur J Med Plants. 2016;14(3):1–7.
  15. Anburaj J, Tamilselvi E, Swapna S, Amuthavalli K. β-Amyrin modulates P38 MAPK and JNK pathway to inhibit cell proliferation and induce ROS-mediated apoptosis in HeLa cells. Indian J Pharm Sci. 2020;82(3).
  16. Gonçalves CF, Hecht F, Cazarin J, Fortunato RS, Vaisman M, de Carvalho DP, et al. The flavonoid quercetin reduces cell migration and increases NIS and E-cadherin mRNA in the human thyroid cancer cell line BCPAP. Mol Cell Endocrinol. 2021; 529:111266.
Regular Issue Subscription Original Research
Volume 02
Issue 02
Received 20/01/2025
Accepted 29/04/2025
Published 05/05/2025
Publication Time 105 Days
31

[last_name]

My IP

PlumX Metrics